This 1.5-hour CE webinar, hosted by Making a Difference in Infectious Diseases (MAD-ID), also offers the opportunity to earn BCIDP recertification credit through the Society of Infectious Diseases Pharmacists (SIDP). This activity will focus on important aspects of recent clinical practice guideline updates for management of asymptomatic bacteriuria and community-acquired pneumonia – including epidemiology, new or updated management recommendations, remaining clinical controversies, and antimicrobial stewardship considerations.
The target audience for this activity includes pharmacists and board-certified infectious diseases pharmacists (BCIDPs) seeking to update their knowledge and skills related to contemporary infectious diseases literature review. At the completion of this activity, the participant will be able to:
- Describe the conditions and patient populations for asymptomatic bacteriuria
- Discuss the issues and drawbacks to treating asymptomatic bacteriuria
- List the instances where asymptomatic bacteriuria should be treated
- Describe the overall management issues surrounding the treatment of CAP
- Review the major changes in the CAP treatment guidelines
- Discuss controversies that still remain to be answered regarding the treatment of CAP
John A. Bosso, PharmD, FCCP, FIDSA, FIDP
Medical University of South Carolina
Colleges of Pharmacy and Medicine
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
Summa Health and Northeast Ohio Medical University
Emily S. Spivak, MD, MHS, FIDSA
University of Utah College of Medicine
Salt Lake City, UT
Release Date: September 8, 2020
Expiration Date: September 8, 2021
Pharmacist CE is provided by MAD-ID. UAN #: 0485-0000-20-024-H01-P. MAD-ID is accredited by the Accreditation Council for Pharmacy Education as the provider of continuing pharmacy education. 1.5 CEU will be awarded to those participants passing a post-event learning assessment quiz.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 09/08/2020 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the Society of Infectious Diseases Pharmacists (SIDP), the joint program offered by the American College of Clinical Pharmacy (ACCP), and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Neither the moderator nor the speakers have any significant financial relationships to report relevant to the content of this program.
General educational grants supporting this activity have been provided by Merck Sharp & Dohme Corp. and Cepheid.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
LIVE Webinar Attendance (Enter Event/Attendance Code provided after webinar to verify attendance)
|Date||9/8/2020 12:00:00 PM|